Abstract
Ganoderic acids (GAs) produced by Ganoderma lucidum exhibit antitumor and antimetastasis activities. This study aimed to improve the production of individual GAs by engineering the biosynthetic pathway of GAs in G. lucidum through the overexpression of squalene synthase (SQS) gene. SQS catalyzes the first enzymatic step from the mevalonate pathway toward triterpene biosynthesis. The effects of SQS gene overexpression on the accumulation of individual GAs and their intermediates (squalene and lanosterol) by a submerged culture of G. lucidum and on the transcription levels of GA biosynthesis genes in this mushroom were investigated. The maximum contents of GA-Mk, GA-T, GA-Me, and GA-S in G. lucidum overexpressing the SQS gene were 16, 40, 43, and 53μg/100mg dry cell weight, respectively, which were 2.86-, 2.67-, 1.95-, and 1.25-fold of those obtained in wild-type strain (WT). The maximum contents of squalene and lanosterol in the SQS gene-overexpression strain were 1.55- and 1.68-fold higher than those of the WT strain. The transcription levels of the biosynthetic genes encoding SQS and lanosterol synthase were up-regulated by 15.6- and 1.93-fold, respectively, in G. lucidum overexpressing the SQS gene, suggesting that increased GA biosynthesis may result from a higher expression of those genes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.